Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1

Status

Withdrawn 1Unknown 1Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 8Genitourinary 3Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Classical hematology 1

Conditions

Carcinoma, Renal Cell 37Parkinson Disease 4, Autosomal Dominant Lewy Body 7Neoplasm Metastasis 4Kidney Neoplasms 4Carcinoma, Transitional Cell 4Squamous Cell Carcinoma of Head and Neck 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Ovarian Neoplasms 2Melanoma 2Clear-cell metastatic renal cell carcinoma 2Brain Neoplasms 2von Hippel-Lindau Disease 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Penile Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1

Interventions

pembrolizumab 27Docetaxel 20Cyclophosphamide 18Surveys and Questionnaires 15Therapeutics 14Radiotherapy 13Paclitaxel 12Psychiatric Rehabilitation 11Early Intervention, Educational 11Carboplatin 11Standard of Care 10olaparib 9Zoledronic Acid 9Specimen Handling 9Radiosurgery 9Magnetic Resonance Spectroscopy 9Interviews as Topic 9Gemcitabine 9Trastuzumab 8Methods 8Fulvestrant 8palbociclib 7fludarabine 7durvalumab 7Taxes 7Nivolumab 7Fluorodeoxyglucose F18 7Flow Cytometry 7Educational Status 7Blood Specimen Collection 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Neoplasms × lenvatinib × Genitourinary × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05949424 2023-11-29

OPTI-DOSE

University Medical Center Groningen

Phase 4 Unknown
30 enrolled
BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Carcinoma, Renal Cell, Ovarian Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT02915172 2017-06-26

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Withdrawn
BreastGenitourinary

Breast Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡